Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07115706) titled 'JAQBO(R) Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD' on Aug. 4.
Study Type: Observational [Patient Registry]
Primary Sponsor: Jeil Pharmaceutical Co., Ltd.
Condition:
Erosive Gastroesophageal Reflux Disease
Recruitment Status: Not recruiting
Date of First Enrollment: August 25, 2025
Target Sample Size: 7150
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07115706
Published by HT Digital Content Services with permission from Health Daily Digest....